CCPG1 Inhibitors
CCPG1 inhibitors encompass a group of chemical compounds designed to selectively interfere with the function of the cellular cyclophilin-like protein, CCPG1. By targeting CCPG1, these inhibitors disrupt its role in various cellular processes without affecting other cyclophilins, allowing for a more precise modulation of its activity. The mode of action of CCPG1 inhibitors typically involves binding to the active site of the protein, which in turn affects its peptidyl-prolyl cis-trans isomerase activity. This inhibition can alter the folding and function of specific proteins that require CCPG1 for proper conformation, impacting processes where CCPG1 is an essential factor. It is important to note that the inhibition of CCPG1 can lead to changes in endoplasmic reticulum stress responses, as CCPG1 is implicated in the regulation of this cellular pathway. By inhibiting CCPG1, these compounds can potentially modulate the unfolded protein response, which is crucial for maintaining cellular homeostasis.
The specificity of CCPG1 inhibitors is key to their function, as they do not broadly affect the entire family of cyclophilins, thus minimizing off-target effects. The selective nature of these inhibitors stems from their molecular structure, which is engineered to fit uniquely into the active site of CCPG1. This selectivity ensures that the inhibitors have a specific effect on processes involving CCPG1 without interfering with other proteins that might have similar structures or functions. The precise inhibition of CCPG1 can lead to alterations in the intracellular signaling pathways that depend on the proper function of this protein. Since CCPG1 interacts with various molecular partners to regulate trafficking and secretion of proteins, its inhibition can result in a cascade of effects within the cell that ultimately influence the efficiency and dynamics of protein processing and movement within the endoplasmic reticulum and beyond.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), a small GTPase involved in vesicle trafficking between the Golgi and the ER. Since CCPG1 is known to be involved in Golgi apparatus maintenance, Brefeldin A's action on ARF can indirectly inhibit CCPG1 by disrupting Golgi-ER function. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is an inhibitor of NEDD8-activating enzyme. Neddylation is a post-translational modification that regulates various cellular processes, including trafficking. Inhibition of neddylation can disrupt protein trafficking in the Golgi, which may indirectly inhibit CCPG1 activity related to Golgi maintenance. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation in the ER. As CCPG1 is involved in maintaining Golgi structure and function, disrupting glycosylation can lead to accumulation of misfolded proteins in the ER, indirectly affecting CCPG1 function by stressing the Golgi apparatus. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF1 GTPase. Since CCPG1 plays a role in Golgi structure, inhibiting GBF1 with Golgicide A disrupts Golgi trafficking and can indirectly affect CCPG1's functional role in the organelle. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits Golgi alpha-mannosidase II, similar to GCA-186, and leads to misfolded glycoproteins. This misfolding can stress the Golgi apparatus and indirectly inhibit CCPG1 activity associated with maintaining Golgi integrity. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 is an exocyst complex inhibitor. The exocyst complex is involved in vesicle tethering during exocytosis. CCPG1, being implicated in Golgi maintenance, may be indirectly inhibited by Exo1 through the disruption of vesicle trafficking at the Golgi, leading to altered Golgi dynamics. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG1478 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. While not directly linked to Golgi function, EGFR signaling can influence various cellular processes including protein trafficking. Inhibiting EGFR may have downstream effects that indirectly inhibit CCPG1 function related to Golgi structure. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a GTPase inhibitor that targets dynamin, involved in clathrin-mediated endocytosis and vesicle trafficking. The inhibition of dynamin can affect CCPG1 indirectly by altering endocytosis and vesicle formation, processes which are crucial for proper Golgi function and maintenance. | ||||||